NASDAQ:CYCC - Cyclacel Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cyclacel Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.60 +0.07 (+13.33 %) (As of 12/8/2019 03:02 AM ET) Add Compare Today's Range$0.54Now: $0.60▼$0.6050-Day Range$0.33MA: $0.43▼$0.5852-Week Range$0.28Now: $0.60▼$1.18Volume219,011 shsAverage Volume399,318 shsMarket Capitalization$10.23 millionP/E RatioN/ADividend YieldN/ABeta3.19 ProfileAnalyst RatingsAdvanced ChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include CYC065, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CYCC Previous Symbol CUSIPN/A CIK1130166 Webhttp://www.cyclacel.com/ Phone908-517-7330Debt Debt-to-Equity Ratio0.08 Current Ratio7.65 Quick Ratio7.65Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$150,000.00 Price / Sales68.22 Cash FlowN/A Price / Cash FlowN/A Book Value$1.22 per share Price / Book0.49Profitability EPS (Most Recent Fiscal Year)($0.62) Net Income$-7,290,000.00 Net MarginsN/A Return on Equity-49.11% Return on Assets-39.36%Miscellaneous Employees14 Outstanding Shares17,199,000Market Cap$10.23 million Next Earnings Date3/25/2020 (Estimated) OptionableNot Optionable Receive CYCC News and Ratings via Email Sign-up to receive the latest news and ratings for CYCC and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:CYCC Rates by TradingView Cyclacel Pharmaceuticals (NASDAQ:CYCC) Frequently Asked Questions What is Cyclacel Pharmaceuticals' stock symbol? Cyclacel Pharmaceuticals trades on the NASDAQ under the ticker symbol "CYCC." When did Cyclacel Pharmaceuticals' stock split? How did Cyclacel Pharmaceuticals' stock split work? Cyclacel Pharmaceuticals shares reverse split on the morning of Tuesday, May 31st 2016. The 1-12 reverse split was announced on Friday, May 27th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 27th 2016. An investor that had 100 shares of Cyclacel Pharmaceuticals stock prior to the reverse split would have 8 shares after the split. How were Cyclacel Pharmaceuticals' earnings last quarter? Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) released its quarterly earnings results on Thursday, August, 9th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by $0.04. View Cyclacel Pharmaceuticals' Earnings History. When is Cyclacel Pharmaceuticals' next earnings date? Cyclacel Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March 25th 2020. View Earnings Estimates for Cyclacel Pharmaceuticals. What is the consensus analysts' recommendation for Cyclacel Pharmaceuticals? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cyclacel Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cyclacel Pharmaceuticals. Has Cyclacel Pharmaceuticals been receiving favorable news coverage? Press coverage about CYCC stock has trended somewhat positive this week, according to InfoTrie Sentiment. The research firm rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cyclacel Pharmaceuticals earned a news impact score of 2.0 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 8.0 out of 10, indicating that recent media coverage is very likely to have an impact on the stock's share price in the near term. View News Stories for Cyclacel Pharmaceuticals. Who are some of Cyclacel Pharmaceuticals' key competitors? Some companies that are related to Cyclacel Pharmaceuticals include Bellicum Pharmaceuticals (BLCM), Evoke Pharma (EVOK), Nemus Bioscience (NMUS), Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (ZOM), Alimera Sciences (ALIM), Acer Therapeutics (ACER), Sierra Oncology (SRRA), Sunesis Pharmaceuticals (SNSS), DiaMedica Therapeutics (DMAC), Edesa Biotech (EDSA), Adamis Pharmaceuticals (ADMP), Celsion (CLSN), Teligent (TLGT), Akari Therapeutics (AKTX) and Jaguar Health (JAGX). What other stocks do shareholders of Cyclacel Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cyclacel Pharmaceuticals investors own include McEwen Mining (MUX), Synergy Pharmaceuticals (SGYP), Celldex Therapeutics (CLDX), NovaBay Pharmaceuticals (NBY), Novavax (NVAX), Exelixis (EXEL), Bausch Health Companies (BHC), Mateon Therapeutics (MATN), SLS International (SLS) and Caladrius Biosciences (CLBS). Who are Cyclacel Pharmaceuticals' key executives? Cyclacel Pharmaceuticals' management team includes the folowing people: Mr. Spiro George Rombotis, Pres, CEO & Exec. Director (Age 60)Mr. Paul McBarron, Exec. VP of Fin., CFO, COO, Sec. & Exec. Director (Age 58)Dr. Judy H. Chiao, VP of Clinical Devel. & Regulatory Affairs (Age 59)Ms. Gill Christie, Director of HR (Age 62)Dr. Robert Westwood Ph.D., Head of Preclinical Devel. and VP of Chemistry & Preclinical Devel. (Age 75) How do I buy shares of Cyclacel Pharmaceuticals? Shares of CYCC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Cyclacel Pharmaceuticals' stock price today? One share of CYCC stock can currently be purchased for approximately $0.60. How big of a company is Cyclacel Pharmaceuticals? Cyclacel Pharmaceuticals has a market capitalization of $10.23 million and generates $150,000.00 in revenue each year. The biotechnology company earns $-7,290,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. Cyclacel Pharmaceuticals employs 14 workers across the globe.View Additional Information About Cyclacel Pharmaceuticals. What is Cyclacel Pharmaceuticals' official website? The official website for Cyclacel Pharmaceuticals is http://www.cyclacel.com/. How can I contact Cyclacel Pharmaceuticals? Cyclacel Pharmaceuticals' mailing address is 200 CONNELL DRIVE SUITE 1500, BERKELEY HEIGHTS NJ, 07922. The biotechnology company can be reached via phone at 908-517-7330 or via email at [email protected] MarketBeat Community Rating for Cyclacel Pharmaceuticals (NASDAQ CYCC)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 152 (Vote Outperform)Underperform Votes: 179 (Vote Underperform)Total Votes: 331MarketBeat's community ratings are surveys of what our community members think about Cyclacel Pharmaceuticals and other stocks. Vote "Outperform" if you believe CYCC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYCC will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/8/2019 by MarketBeat.com StaffFeatured Article: What impact do institutional investors have on markets?
